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signature for aneuploidy
Ivan Bièche1,2*, Sophie Vacher1, François Lallemand1, Sengül Tozlu-Kara1, Hind Bennani1, Michèle Beuzelin1,
Keltouma Driouch1, Etienne Rouleau1, Florence Lerebours1, Hugues Ripoche3, Géraldine Cizeron-Clairac1,
Frédérique Spyratos1, Rosette Lidereau1
Abstract
Background: Aneuploidy and chromosomal instability (CIN) are common abnormalities in human cancer.
Alterations of the mitotic spindle checkpoint are likely to contribute to these phenotypes, but little is known about
somatic alterations of mitotic spindle checkpoint genes in breast cancer.
Methods: To obtain further insight into the molecular mechanisms underlying aneuploidy in breast cancer, we
used real-time quantitative RT-PCR to quantify the mRNA expression of 76 selected mitotic spindle checkpoint
genes in a large panel of breast tumor samples.
Results: The expression of 49 (64.5%) of the 76 genes was significantly dysregulated in breast tumors compared to
normal breast tissues: 40 genes were upregulated and 9 were downregulated. Most of these changes in gene
expression during malignant transformation were observed in epithelial cells.
Alterations of nine of these genes, and particularly NDC80, were also detected in benign breast tumors, indicating
that they may be involved in pre-neoplastic processes.
We also identified a two-gene expression signature (PLK1 + AURKA) which discriminated between DNA aneuploid
and DNA diploid breast tumor samples. Interestingly, some DNA tetraploid tumor samples failed to cluster with
DNA aneuploid breast tumors.
Conclusion: This study confirms the importance of previously characterized genes and identifies novel candidate
genes that could be activated for aneuploidy to occur. Further functional analyses are required to clearly confirm
the role of these new identified genes in the molecular mechanisms involved in breast cancer aneuploidy. The
novel genes identified here, and/or the two-gene expression signature, might serve as diagnostic or prognostic
markers and form the basis for novel therapeutic strategies.
Introduction
A very large proportion of cancers consist of cells with
an abnormal chromosome content, a feature known as
aneuploidy [1]. Aneuploidy is often associated with
chromosomal instability (CIN), a condition in which
cancer cells show a high rate of chromosomal gain and
loss compared with normal cells.
The mechanisms underlying CIN, although poorly
understood, are likely to include defects in the mitotic
machinery used to segregate duplicated chromosomes
between daughter cells [2]. Mounting evidence points to
the mitotic spindle checkpoint as the point of failure in
CIN. The normal function of the spindle checkpoint is
to ensure that all chromosomes are correctly aligned in
metaphase cells and properly attached to the mitotic
spindle before chromosome separation can proceed.
Like other phenotypes characteristic of cancer, it was
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first thought that nucleotide mutations in genes that
control chromosome stability were responsible for CIN.
However, somatic point mutations in mitotic-spindle-
checkpoint genes, including MAD1, BUB1 and BUBR1/
BUB1B, are infrequent [3]. One possible explanation for
this paradox is that mitotic-spindle-checkpoint genes
are mainly altered at the transcriptional level. Indeed,
amplification and overexpression of AURKA (which
encodes aurora-A kinase) have been observed in breast
tumors and other cancers exhibiting aneuploidy [4].
PLK1 and NEK2 mRNA and protein expression is also
elevated in a wide variety of tumors and cancer cell
lines [5,6]. However, despite the importance of the mito-
tic spindle checkpoint in CIN, no detailed analyses of
mitotic spindle checkpoint gene expression in tumors
has yet been performed.
The recent development of effective tools for large-scale
analysis of gene expression is providing new insights into
the involvement of gene networks and regulatory pathways
in various tumor processes [7]. It has also led to the dis-
covery of new diagnostic and prognostic indicators, and to
the identification of new molecular targets for drug devel-
opment [8]. These tools include cDNA microarrays, which
can be used to explore the expression of thousands of
genes at a time, and real-time RT-PCR assays for more
accurate quantitative studies of the expression of a smaller
number of selected candidate genes.
As aneuploidy is common in breast cancer and is
associated with a poor prognosis [9], we examined the
expression of selected mitotic spindle checkpoint genes
in breast tumors. We used real-time quantitative RT-
PCR to measure the mRNA expression of a large num-
ber of selected genes in DNA aneuploid breast tumor
samples, in comparison with DNA diploid breast tumor
samples. We assessed the expression level of 76 genes
known to be involved in various molecular mechanisms
associated with the mitotic spindle checkpoint (Table 1).
We identified nine genes involved in early breast tumor-
igenesis, and also a two-gene expression signature
(PLK1 + AURKA) associated with aneuploid status.
Results
MRNA expression of 76 mitotic-spindle-checkpoint genes
in invasive breast tumors relative to normal breast tissue
To select for further study those mitotic-spindle-check-
point genes whose expression is dysregulated in breast
tumors, we quantified the mRNA expression of the 76
selected genes in 10 invasive breast tumors relative to 5
normal breast tissues.
MRNA of all 76 genes was reliably quantifiable by
means of real-time quantitative RT-PCR (Ct < 35) in
both invasive breast tumors and normal breast tissues.
Forty (52.6%) of the 76 genes were significantly upre-
gulated (P < 0.05) in the invasive breast tumors
compared to the normal breast tissues (Table 2). The
expression of 20 of these 40 upregulated genes was
markedly higher (> 3-fold) in the breast tumors. The
most strongly upregulated gene was NEK2 (29-fold).
In contrast, only 9 (11.8%) of the 76 genes were signif-
icantly down-regulated (P < 0.05) in the invasive breast
tumors compared to the normal breast tissues, and
none showed markedly lower expression (> 3-fold) in
the breast tumors.
Relationship between the mRNA expression of the 20
markedly upregulated genes and steps of breast tumor
progression
To determine whether the 20 genes showing marked
upregulation (> 3-fold) in the invasive breast tumors are
altered at an early step of breast tumorigenicity, we ana-
lyzed their mRNA expression in 9 normal breast tissues,
14 benign breast tumors, 14 ductal carcinoma in situ
(DCIS) of the breast, 11 invasive ductal grade I breast
tumors and 12 invasive ductal grade III breast tumors
(Table 3).
The mRNA levels of 9 of the 20 selected genes (i.e.
NDC80, BUB1, BUB1B, CCNB1, TACC3, TPX2,
CCNA2, CDC2 and CDC20) was significantly increased
in the benign breast tumors as compared to the normal
breast tissues (Table 3). NDC80 was the gene with the
strongest upregulation (3.6-fold).
With the exception of CCNB3, the expression of all 20
genes increased from benign breast tumors to DCIS.
Only TACC3, NEK2, AURKA and PLK1 expression
increased from benign breast tumors to invasive ductal
grade I breast tumors, while expression of all 20 genes
(except CCNB3 and UBD) increased from grade I to
ductal grade III breast tumors.
Figure 1 shows the mRNA levels of three characteris-
tic genes (NDC80, NEK2 and AURKB) in the different
sample types. Figure 2 shows the order in which these
genes are dysregulated during the different steps of
breast tumor progression.
In the same set of 60 samples, we also examined the
expression of the proliferation-associated gene MKI67,
which encodes the proliferation-related antigen Ki-67.
MKI67 only showed significant overexpression in ductal
carcinoma in situ (DCIS) and invasive ductal grade III
breast tumors (Table 3).
MRNA expression of the 20 markedly upregulated genes
in breast cancer cell lines and in primary cultures of
epithelial cells and fibroblasts from normal breast tissues
and breast tumor cells
To determine in which tumor cell type (epithelial cells
or stromal cells) the mitotic-spindle-checkpoint genes
were upregulated, we measured the RNA levels of the
20 markedly upregulated genes in 12 breast cancer cell
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Table 1 List of the 76 selected genes
Gene symbols Alternative symbols Chromosome location Genbank accession
Mitotic spindle formation (n = 16)
AURKAa Aurora-A, STK15, STK6 20q13.2-q13.3 NM_003600
AURKAIP1 AKIP 1p36.33 NM_017900
AURKB Aurora-B; Aurora-1, STK12 17p13.1 NM_004217
AURKC Aurora-C, STK13 19q13.43 NM_003160
BIRC5 Survivin 17q25 NM_001168
CDC20 Fizzy-R, fzy, p55CDC 1p34.1 NM_001255
CLASP1 2q14.2 NM_015282
CLASP2 3p22.3 NM_015097
FBXW7 AGO, hCDC4 4q31.3 NM_033632
FZR1 HCDH1 19p13.3 NM_016263
KNTC1 Rough Deal/ROD 12q24.31 NM_014708
RASSF1A 3p21.3 NM_007182
TPX2 C20orf 20q11.2 NM_012112
ZW10 Zeste-White 11q23.3 NM_004724
ZWILCH FLJ10036 15q22.31 NM_017975
ZWINT ZW10 interactor 10q21-q22 NM_007057
Centrosome cohesion and duplication (n = 2)
CEP250 CEP2, C-NAP1 20q11.22 NM_007186
NEK2 NLK1 1q31.2-q41 NM_002497
Kinetochore-mitotic spindle interaction (n = 19)
BUB1 2q14 NM_004336
BUB1B BUBR1 15q15 NM_001211
BUB3 10q26 NM_004725
CENPE CENP-E 4q24-q25 NM_001813
CSE1L CAS 20q13 NM_001316
FBXO5 Emi1 6q25-q26 NM_012177
MAD1L1 MAD1 7p22 NM_003550
MAD2L1 MAD2 4q27 NM_002358
MAD2L2 REV7, MAD2B 1p36 NM_006341
NDC80 HEC1 18p11.31 NM_006101
PRCC 1q21.1 NM_005973
RAE1 20q13.31 NM_003610
RAN 12q24.3 NM_006325
RCC1 CHC1, RCC1 1p36.1 NM_001269
TACC1 8p11 NM_006283
TACC2 10q26 NM_206862
TACC3 4p16.3 NM_006342
TTK MPS1 kinase 6q13-q21 NM_003318
UBD FAT10 6p21.3 NM_006398
CDK-cyclin complexes (n = 7)
CCNA1 Cyclin A1 13q12.3-q13 NM_003914
CCNA2 Cyclin A2 4q25-q31 NM_001237
CCNB1 Cyclin B1 5q12 NM_031966
CCNB2 Cyclin B2 15q21.2 NM_004701
CCNB3 Cyclin B3 Xp11 NM_033031
CDKN1A p21(WAF1/CIP1) 6p21.2 NM_000389
CDC2 CDK1 10q21.1 NM_001786
Sister chromatid separation - mitotic exit (n = 29)
ANAPC1 APC1 2q12.1 NM_022662
ANAPC10 APC10 4q31 NM_014885
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lines (five ERa-positive and seven ERa-negative cell
lines). As compared to normal breast tissues, all 20
selected genes (except UBD) showed marked upregula-
tion in the 12 breast cancer cell lines (median 3.9- to
87-fold), suggesting that these 19 genes are expressed in
epithelial cells and upregulated in tumor epithelial cells
(Table 4).
Interestingly, the expression of these genes was gener-
ally higher in ERa-negative breast tumor cell lines than
in ERa-positive lines. Despite the small number of cell
lines analysed, seven genes (AURKB, TPX2, CDC20,
BUB1, CCNA2, AURKA, and CCNB1) were upregulated
significantly (p < 0.05) more strongly in the ERa-nega-
tive cell lines. These genes are probably not estrogen-
regulated, but are rather upregulated mainly in undiffer-
entiated breast tumors (i.e. ERa-negative tumors), inde-
pendently of ERa status. Individual expression levels of
these genes in the 12 breast tumor cell lines are shown
in Additional File 1.
As tumors are composed not only of tumor epithelial
cells but also of fibroblasts (the main cell type of the stro-
mal compartment), we also measured the expression of the
same 20 genes in primary cultures of epithelial cells and
fibroblasts from normal breast tissues and breast tumor
cells. We confirmed that these genes were expressed in
epithelial cells and, to a lesser extent, in stromal fibroblasts,
and that they were all upregulated in tumor epithelial cells,
as compared to normal epithelial cells (Table 4).
Relationship between the mRNA expression level and
DNA amplification level of the 20 markedly upregulated
genes
One of the 20 markedly upregulated genes (AURKA) has
previously been shown to be upregulated by a DNA
amplification mechanism [4]. Thus, to obtain further
insight into the molecular mechanisms leading to over-
expression of these 20 markedly upregulated genes, we
used both real-time quantitative RT-PCR and high
Table 1 List of the 76 selected genes (Continued)
ANAPC11 APC11 17q25.3 NM_016476
ANAPC2 APC2 9q34.3 NM_013366
ANAPC4 APC4 4p15.2 NM_013367
ANAPC5 APC5 12q24.31 NM_016237
ANAPC7 APC7 12q13.12 NM_016238
CDC16 APC6 13q34 NM_003903
CDC23 APC8 5q31 NM_004661
CDC26 9q32 NM_139286
CDC27 APC3 17q12-17q23.2 NM_001256
CDC34 19p13.3 NM_004359
ESPL1 Separase 12q13 NM_012291
HSPB1 HSP27 7q11.23 NM_001540
NEDD8 14q11.2 NM_006156
PLK1 Polo-like kinase 1 16p12.1 NM_005030
PPP1CA PPP1A 11q13 NM_002708
PPP1R2 Inh2 3q29 NM_006241
PTTG1 Securin 5q35.1 NM_004219
RAD21 SCC1, KIAA0078 8q24 NM_006265
RNF2 Ding 1q25.3 NM_007212
SMC1A SMC1L1 Xp11.22-p11.21 NM_006306
SMC1B SMC1L2 22q13.31 NM_148674
SMC3 CSPG6 10q25 NM_005445
STAG1 SA1 (stromal antigen 1) 3q22.2 NM_005862
STAG2 SA2 (stromal antigen 2) Xq25 NM_006603
UBE1C UBA3 3p24.3-p13 NM_003968
UBE2B UBE2B 5q23q-31 NM_003337
UBE2N 12q22 NM_003348
Double-strand break repair (n = 3)
MRE11A MRE11 11q21 NM_005590
BRCA1 17q21 NM_007294
BRCA2 13q12.3 NM_000059
a
Entrez Gene symbol.
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resolution array CGH to quantify the mRNA expression
and DNA amplication of these genes in a series of 39
breast tumors (Table 5). Five of these genes (NEK2,
PLK, BIRC5, TPX2 and AURKA) displayed DNA amplifi-
cation (or polysomy) in more than 30% of breast
tumors. Interesting, 3 of these 5 genes (BIRC5, TPX2
and AURKA) showed significantly higher mRNA levels
in amplified tumors than in unamplified tumors. It is
noteworthy that the other two genes (NEK2 and PLK),
that showed similar mRNA levels in amplified and
unamplified breast tumors, are located on chromosome
arms (1q and 16p, respectively) showing polysomy and
no DNA amplification in breast tumors [10,11].
MRNA expression of the 49 dysregulated genes in 23
individual DNA aneuploid breast tumors and 24 DNA
diploid breast tumors
The expression level of the 49 dysregulated genes identi-
fied in our screening study was then determined in a
Table 2 mRNA expression of 76 mitotic-spindle-
checkpoint genes in invasive breast tumors relative to
normal breast tissues
Genes Normal breast tissues
(n = 5)
Invasive breast tumors
(n = 10)
pa
NEK2 1.0 (0.44-2.23) 28.79 (7.41-162.02)b < 0.01
UBD 1.0 (0.31-1.91) 16.95 (1.38-42.32) < 0.01
TPX2 1.0 (0.59-1.48) 13.01 (5.51-144.34) < 0.01
CENPE 1.0 (0.02-2.06) 11.01 (2.41-42.62) < 0.01
CCNB2 1.0 (0.64-1.95) 10.36 (3.14-73.18) < 0.01
BIRC5 1.0 (0.37-2.00) 9.45 (3.64-136.55) < 0.01
NCD80 1.0 (0.29-1.23) 9.24 (2.08-114.83) < 0.01
BUB1 1.0 (0.53-1.51) 8.52 (2.22-58.49) < 0.01
CCNA2 1.0 (0.56-1.90) 8.08 (4.10-52.35) < 0.01
CDC2 1.0 (0.68-1.66) 7.62 (2.59-44.74) < 0.01
BUB1B 1.0 (0.53-1.69) 7.44 (2.47-35.02) < 0.01
TTK 1.0 (0.71-2.08) 6.47 (1.27-36.76) < 0.01
AURKB 1.0 (0.90-2.08) 5.56 (2.02-81.20) < 0.01
PLK1 1.0 (0.60-1.87) 5.52 (2.72-44.53) < 0.01
AURKA 1.0 (0.36-1.33) 4.76 (3.00-39.85) < 0.01
TACC3 1.0 (0.54-2.08) 4.70 (1.73-21.06) < 0.01
CCNB3 1.0 (0.96-4.20) 4.62 (0.80-39.31) < 0.05
ZWINT 1.0 (0.62-1.97) 4.28 (1.78-21.76) < 0.01
CCNB1 1.0 (0.42-2.32) 4.03 (1.10-15.63) < 0.01
CDC20 1.0 (0.61-1.28) 3.51 (0.89-21.21) < 0.05
PRCC 1.0 (0.70-1.27) 2.70 (2.27-4.87) < 0.01
CDKN1A 1.0 (0.61-2.57) 2.43 (1.04-5.59) < 0.05
RAN 1.0 (0.59-1.92) 2.42 (1.23-6.57) < 0.01
ESPL1 1.0 (0.34-1.85) 2.27 (1.23-8.79) < 0.05
PTTG1 1.0 (0.82-1.35) 2.25 (1.61-11.24) < 0.01
KNTC1 1.0 (0.71-1.30) 2.21 (0.80-4.83) < 0.05
BRCA2 1.0 (0.70-1.41) 2.17 (0.68-5.86) < 0.05
RAE1 1.0 (0.81-1.48) 2.16 (1.37-3.48) < 0.01
MAD2L1 1.0 (0.65-1.30) 2.11 (1.16-5.25) < 0.01
AURKAIP1 1.0 (0.94-1.59) 1.96 (1.30-4.68) < 0.01
PPP1CA 1.0 (0.65-1.55) 1.95 (1.47-3.31) < 0.01
BUB3 1.0 (0.65-1.20) 1.87 (1.27-5.64) < 0.01
ANAPC7 1.0 (0.61-1.32) 1.77 (1.59-2.36) < 0.01
CDC27 1.0 (0.57-1.36) 1.67 (1.19-2.32) < 0.01
ZWILCH 1.0 (0.88-1.33) 1.63 (0.75-3.93) < 0.05
PPP1R2 1.0 (067-1.18) 1.55 (0.81-2.06) < 0.05
MAD2L2 1.0 (0.37-1.20) 1.45 (0.69-7.28) < 0.05
UBE1C 1.0 (0.84-1.03) 1.40 (1.07-1.93) < 0.01
UBE2N 1.0 (0.77-1.09) 1.31 (1.29-2.83) < 0.01
CDC23 1.0 (0.71-1.18) 1.21 (0.79-1.53) < 0.05
SMC1B 1.0 (0.43-1.81) 2.89 (0.07-10.65) NS
HSPB1 1.0 (0.66-1.47) 2.03 (0.66-6.79) NS
TACC2 1.0 (0.94-2.30) 1.70 (0.69-4.27) NS
ANAPC11 1.0 (0.13-2.41) 1.65 (0.80-3.95) NS
CSE1L 1.0 (0.61-1.23) 1.59 (0.75-3.87) NS
RAD21 1.0 (0.71-1.17) 1.58 (0.57-8.38) NS
SMC3 1.0 (0.71-1.45) 1.56 (0.59-3.26) NS
RCC1 1.0 (0.39-1.68) 1.54 (0.87-3.75) NS
FBXO5 1.0 (0.42-1.35) 1.50 (0.65-4.52) NS
Table 2 mRNA expression of 76 mitotic-spindle-check-
point genes in invasive breast tumors relative to normal
breast tissues (Continued)
BRCA1 1.0 (0.75-1.29) 1.37 (0.58-5.67) NS
ANAPC10 1.0 (0.56-1.65) 1.34 (0.88-1.75) NS
CEP250 1.0 (0.87-1.54) 1.33 (0.88-3.08) NS
RNF2 1.0 (0.96-1.13) 1.33 (0.64-2.88) NS
CDC34 1.0 (0.33-1.52) 1.23 (0.63-1.97) NS
ANAPC1 1.0 (0.75-1.43) 1.22 (0.54-1.59) NS
SMC1A 1.0 (0.67-1.05) 1.09 (0.56-1.98) NS
UBE2B 1.0 (0.72-1.77) 1.09 (0.41-2.11) NS
NEDD8 1.0 (0.34-1.61) 1.08 (0.30-2.13) NS
ANAPC5 1.0 (0.61-1.13) 1.07 (0.94-1.34) NS
ZW10 1.0 (0.39-1.01) 1.07 (0.63-3.39) NS
STAG2 1.0 (0.76-2.53) 1.05 (0.33-2.15) NS
CDC16 1.0 (0.66-1.19) 0.99 (0.57-1.52) NS
CLAPS2 1.0 (0.84-1.31) 0.98 (0.61-1.74) NS
CDC26 1.0 (0.46-1.41) 0.97 (0.61-1.53) NS
CLASP1 1.0 (0.84-1.54) 0.93 (0.71-1.45) NS
CCNA1 1.0 (0.28-1.06) 0.84 (0.41-3.69) NS
MAD1L1 1.0 (0.37-1.13) 0.69 (0.42-1.12) NS
TACC1 1.0 (0.92-2.06) 0.78 (0.63-1.33) < 0.05
ANAPC2 1.0 (0.40-1.23) 0.77 (0.62-1.45) < 0.05
FZR1 1.0 (0.40-1.29) 0.73 (0.51-1.18) < 0.05
STAG1 1.0 (0.68-1.14) 0.69 (0.36-1.00) < 0.05
ANAPC4 1.0 (0.52-1.10) 0.68 (0.43-1.08) < 0.05
MRE11A 1.0 (0.90-1.23) 0.64 (0.26-1.23) < 0.05
FBXW7 1.0 (0.84-1.29) 0.56 (0.41-1.14) < 0.05
AURKC 1.0 (0.63-1.43) 0.49 (0.34-2.66) < 0.05
RASSF1 1.0 (0.17-3.10) 0.44 (0.12-1.68) < 0.05
aMann and Whitney’s U Test.
bMedian (range) of gene mRNA levels. The mRNA levels of the tumor samples
were normalized such that the median of the 5 normal breast tissues mRNA
levels was 1.
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series of 23 DNA aneuploid breast tumors and 24 DNA
diploid breast tumors (Table 6).
Twenty-four (49.0%) of the 49 dysregulated genes were
significantly upregulated in the 23 DNA aneuploid breast
tumors relative to the DNA diploid breast tumors, while
only one gene (FZR1) among the 49 dysregulated genes
was significantly down-regulated (P < 0.05; Table 7).
In the same set of 47 samples, we examined the expres-
sion of MKI67 and ESR1/ERa. As CIN of cancer cells
could also be caused by telomere erosion [12], we exam-
ined the expression of the TERT gene encoding telomer-
ase reverse transcriptase. MKI67 and TERT were
significantly upregulated in the 23 DNA aneuploid breast
tumors, while ESR1/ERa expression was similar in the
diploid and aneuploid breast tumor subgroups (Table 7).
Prediction Analysis for Microarrays (PAM) and Class
Prediction results obtained with the BRB Array Tools
software packages were then used to identify a gene
expression signature capable of discriminating between
DNA aneuploid and DNA diploid breast tumors. Class
Prediction identified a signature composed of 8 genes
(PLK1, AURKA, CCNB1, BUB1, TACC3, CDC20, CDC2
and TPX2), while PAM identified a signature composed
of only two genes (PLK1 and AURKA) that were also
present in the Class Prediction signature.
Finally, hierarchical clustering of the 47 samples, based
on PLK1 and AURKA expression, subdivided the patient
population into three groups with significantly different
ploidy (P = 0.0000015; figure 3), namely a DNA diploid
group of 17 tumors (all but one showing DNA diploid
status), an intermediate group of 11 tumors (7 DNA
diploid and 4 DNA aneuploid) and a DNA aneuploid
group of 19 tumors (all but one showing DNA aneuploid
status). Interestingly, the SPF value of the DNA aneu-
ploid tumor (5449-A; dotted line rectangle in figure 3) in
the DNA diploid group was low, while the SPF values of
the 8 DNA diploid tumors (solid line rectangles in figure 3)
in the DNA aneuploid and intermediate groups were high
(except for one with an intermediate SPF value).
Validation of the two-gene expression signature in an
independent series of breast tumor samples
To validate our two-gene expression signature for tumor
ploidy, we analyzed six additional classical DNA aneu-
ploid breast tumors (1.10 ≤ ploidy index ≤ 1.90). All six
tumors fell into the DNA aneuploid group (n = 5) or
Table 3 Relationship between mRNA levels of 20 markedly upregulated genes and breast cancer progression
Genes Normal
breast tissues
(n = 9)
Benign breast
tumors
(n = 14)
pa DCIS of the breast
(n = 14)
pb Invasive grade I
breast tumors
(n = 11)
pc Invasive grade III
breast tumors
(n = 12)
pd
NDC80 1,0 (0,00-1,39) 3,64 (1,32-17,79)e <0,01 14,55 (4,10-24,20) 0,0009 7,11 (1,38-13,55) NS 15,22 (4,76-54,69) 0,01
BUB1 1,0 (0,00-1,38) 2,97 (1,52-14,03) <0,01 15,37 (1,59-94,35) 0,001 6,59 (0,00-94,35) NS 17,54 (5,46-57,28) 0,004
BUB1B 1,0 (0,24-2,97) 2,72 (1,01-9,38) <0,01 14,54 (3,53-39,95) 0,0002 6,11 (0,00-11,31) NS 18,66 (2,39-105,05) 0,004
CCNB1 1,0 (0,00-3,14) 2,51 (1,01-6,82) <0,01 6,82 (1,71-15,24) 0,002 4,23 (1,33-5,90) NS 9,05(3,51-41,64) 0,007
TACC3 1,0 (0,00-1,35) 1,70 (0,78-6,18) <0,01 7,21 (1,77-13,67) 0,0003 5,31 (1,11-11,24) 0,02 17,04 (4,98-74,03) 0,0006
TPX2 1,0 (0,31-4,23) 2,84 (0,82-10,73) <0,05 16,99 (4,70-35,59) 0,00009 6,51 (1,67-19,74) NS 23,84 (6,15-315,17) 0,0009
CCNA2 1,0 (0,05-1,45) 2,19 (0,20-7,19) <0,05 10,56 (1,70-17,21) 0,0006 3,36 (1,04-8,34) NS 11,38 (1,64-104,33) 0,008
CDC2 1,0 (0,00-2,11) 1,76 (0,76-7,36) <0,05 10,16 (2,56-20,87) 0,00008 6,01 (1,06-10,78) NS 10,99 (3,32-56,75) 0,006
CDC20 1,0 (0,06-1,28) 1,67 (0,63-3,54) <0,05 3,90 (1,49-14,09) 0,0001 1,65 (1,76-3,00) NS 6,14 (1,76-142,68) 0,0002
NEK2 1,0 (0,16-2,87) 1,17 (0,41-3,78) NS 10,44 (2,03-26,23) 0,00004 2,67 (1,15-11,88) 0,008 14,83 (3,60-115,09) 0,0006
AURKA 1,0 (0,30-2,58) 1,12 (0,33-2,32) NS 6,04 (1,27-21,01) 0,00002 2,54 (1,25-7,16) 0,002 7,82 (2,04-58,89) 0,003
PLK1 1,0 (0,30-2,08) 0,80 (0,34-1,99) NS 3,83 (1,09-11,37) 0,00003 1,91 (0,20-5,66) 0,04 7,09 (1,92-117,27) 0,0009
TTK 1,0 (0,01-7,32) 2,43 (0,00-11,29) NS 9,85 (2,59-32,07) 0,0003 2,32 (0,00-5,68) NS 8,59 (4,14-55,84) 0,0002
AURKB 1,0 (0,00-3,24) 2,07 (0,22-7,41) NS 5,97 (0,99-26,91) 0,02 4,24 (1,05-10,06) NS 16,26 (5,70-210,84) 0,0003
BIRC5 1,0 (0,46-3,40) 1,37 (0,39-6,06) NS 7,86 (1,68-40,50) 0,00008 3,51 -0,54-7,29) NS 12,20 (3,14-128,0) 0,0007
ZWINT 1,0 (0,00-3,71) 1,98 (0,39-4,53) NS 5,70 (2,45-15,74) 0,0002 3,59 (0,89-6,09) NS 10,95 (2,70-55,46) 0,001
CCNB2 1,0 (0,31-1,93) 1,43 (0,70-5,98) NS 8,98 (1,57-23,43) 0,0002 3,31 (0,03-7,31) NS 12,28 (1,53-52,35) 0,005
CENPE 1,0 (0,03-4,58) 0,96 (0,33-6,15) NS 3,61 (1,11-8,34) 0,002 2,00 (0,33-5,57) NS 2,98 (0,84-10,15) 0,04
UBD 1,0 (0,00-3,07) 1,49 (0,34-4,66) NS 3,19 (0,43-4,66) 0,04 2,92 (0,19-14,72) NS 5,30 (1,16-32,37) NS
CCNB3 1,0 (0,00-6,11) 2,52 (0,53-5,82) NS 1,36 (0,00-8,94) NS 3,24 (0,63-8,54) NS 2,71 (0,00-8,54) NS
MKI67 1,0 (0,03-2,87) 2,63 (0,47-12,70) NS 14,92 (2,12-33,98) 0,0007 5,21 (0,13-12,15) NS 14,09 (2,45-189,14) 0,009
aMann et Whitney’s U Test: Benign breast tumors vs Normal breast tissues. NS, not significant.
bDuctal Carcinoma In Situ (DCIS) of the breast vs Benign breast tumors.
cInvasive grade I breast tumors vs Benign breast tumors.
dInvasive grade III breast tumors vs Invasive grade I breast tumors.
eMedian (range) of gene mRNA levels. The mRNA levels of the tumor samples were normalized such that the median of the 9 normal breast tissues mRNA levels
was 1.
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Figure 1 mRNA levels of 3 characteristic upregulated genes (NDC80, NEK2 and AURKA) according to breast tumor progression. Breast
tumor progression groups are consisting of 9 normal breast tissues, 14 benign breast tumors, 14 ductal carcinoma in situ (DCIS), 11 invasive
ductal grade I and 12 invasive ductal grade III breast tumors, respectively. Median values (ranges) and means +/- SD (in italics) are indicated for
each tumor subgroup.
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the intermediate group (n = 1) (figure 4). It is note-
worthy that the DNA aneuploid tumor (5448-T)
included in the intermediate group had a low SPF value.
Recent studies suggest that abnormal division of tetra-
ploid cells might facilitate genetic changes that give rise
to aneuploid cancers and therefore that tetraploidy
could be a transitional step between diploid status and
classical aneuploid status [1]. Thus, we also analyzed 8
DNA tetraploid breast tumors (1.90 ≤ ploidy index ≤
2.05) with our two-gene expression signature. All but
one of these DNA tetraploid breast tumors fell into the
DNA aneuploid group (n = 3) or the intermediate group
(n = 4) (figure 5). It is noteworthy that the DNA tetra-
ploid tumor (5081-T) included in the DNA diploid
group had a low SPF value.
As the validation set includes a limited number of
breast tumor samples, this two-gene expression signa-
ture capable of discriminating between DNA aneuploid
and diploid breast tumors needs to be further validated
in a large prospective randomized study.
Discussion
To obtain further insight into the molecular mechan-
isms leading to aneuploidy in breast cancer, we used
real-time quantitative RT-PCR to quantify the mRNA
expression of a large number of selected genes in var-
ious types of breast tumor.
Real-time quantitative RT-PCR is a promising alterna-
tive to cDNA microarrays for molecular tumor profiling.
In particular, real-time RT-PCR is far more precise,
reproducible and quantitative than cDNA microarrays.
Real-time RT-PCR is also more useful for analyzing
weakly expressed genes, such as TERT in the present
study. Finally, real-time RT-PCR requires smaller
amounts of total RNA (about 2 ng per target gene), and
is therefore suitable for analyzing small (benign or
malignant) and microdissected tumor samples.
We studied a number of genes involved in various
molecular mechanisms associated with the mitotic spin-
dle checkpoint, and particularly genes already known to
be altered (mainly at the transcriptional level) in various
cancers [13-15]. These genes mainly encode proteins
involved in mitotic spindle formation, centrosome cohe-
sion and duplication, kinetochore-mitotic spindle inter-
actions, CDK-cyclin complexes, and sister chromatid
separation (see list in Table 1). This analysis was by no
means exhaustive, and many possibly relevant genes
were certainly missed, but it nevertheless demonstrates
the ability of real-time RT-PCR to identify potentially
useful marker genes.
Among the 76 genes analyzed, 49 (64.5%) showed sig-
nificant dysregulation in breast tumors compared to nor-
mal breast tissues: 40 genes were upregulated (including
20 genes showing marked (> 3-fold) upregulation), while
only nine genes were downregulated, and this downregu-
lation was always moderate (< 3-fold) (Table 2).
To investigate if these genes are involved early in
breast tumorigenesis (i.e. the transition from normal
breast tissue to benign breast tumors and DCIS) or in
tumor progression (i.e. the transition from invasive duc-
tal grade I to invasive ductal grade III breast tumors),
we studied the expression level of the 20 markedly upre-
gulated genes in large panel of breast tissues, including
normal breast tissues, benign breast tumors, DCIS, and
grade I and III invasive ductal breast tumors (Table 3
and Figure 2).
Normal
breast
tissue
Invasive
ductal
grade III
Benign
breast
tissue
Invasive
ductal
grade I
NDC80
BUB1
BUB1B
CCNB1
TACC3
TPX2
CCNA2
CDC2
CDC20
NEK2
AURKA
PLK1
TTK
AURKB
BIRC5
ZWINT
CCNB2
CENPE
Figure 2 Involvement of 18 characteristic genes in different steps of breast tumor progression.
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Like MKI67, which encodes the proliferation-related
antigen Ki-67, the expression of most of these genes
(except CCNB3 and UBD) increased during the transi-
tion from grade I to ductal grade III breast tumors.
Twelve genes (NDC80, BUB1, CDC2, CCNA2, BUB1B,
TACC3, TPX2, ZWINT, CCNB2, AURKB, NEK2 and
BIRC5) showed marked upregulation in ductal grade III
breast tumors (more than 10-fold higher than in normal
breast tissues), as well as in the breast tumor cell lines
(up to 70-fold higher than in normal breast tissues).
Most of these genes were specifically altered in tumor
epithelial cells during malignant transformation.
These results are in total agreement with the literature
showing a strong link between aneuploidy/CIN and
tumor grade, i.e. between mitotic spindle checkpoint
pathways and cell proliferation pathways. Indeed, several
of the mitotic spindle checkpoint genes identified in this
study (in particular TPX2, NEK2, AURKA and PLK1)
have previously been included in a “proliferation signa-
ture” discriminating histological grades I and III [16], or
in a “poor prognosis” signature [17,18].
These genes also showed marked upegulation in DCIS
(higher than in ductal grade I breast tumors), confirm-
ing the major role of mitotic spindle checkpoint genes
in pre-invasive lesions of the most common human can-
cers [19,20].
More interestingly, we identified 9 genes (NDC80,
BUB1, BUB1B, CCNB1, TACC3, TPX2, CCNA2, CDC2
and CDC20) involved in the transition from normal
breast tissues to benign breast tumors (Table 3).
NDC80/HEC1 was the most strongly upregulated gene.
Among the 14 benign breast tumors analyzed, 10
(71.4%) showed significant NDC80/HEC1 overexpression
(> 3-fold higher than in normal breast tissues). NDC80/
HEC1 is thus an outstanding candidate marker of breast
lesions that are likely to undergo malignant transforma-
tion. NDC80/HEC1 regulates kinetochore microtubule
dynamics and attachment stability [21]. Small molecule
targeting Hec1 protein suppresses tumor cell growth in
culture and in animal [22].
We identified a two-gene expression signature (PLK1
+ AURKA) associated with aneuploidy. PLK1 and
AURKA are well-known mitotic spindle checkpoint
genes that encode mitotic kinases (polo-like kinase-1
and aurora A, respectively). These enzymes are emer-
ging as critical regulators of centrosome cycling and for-
mation of the bipolar mitotic spindle [23-25]. These two
genes are overexpressed in many types of solid tumor.
Table 4 mRNA expressions of the 20 markedly upregulated genes in breast cancer cell lines (ERa-negative and
ERa-positive) and in primary cell cultures of epithelial cells and fibroblasts from normal breast tissues and breast
tumor cells
Genes Normal
breast
tissues
(n = 9)
Breast tumor cell
lines
(n = 12)
ERa-negative cell
lines
(n = 7)
ERa-positive cell
lines
(n = 5)
pa Normal
fibroblasts
Normal
epithelial
cells
Tumoral
fibroblasts
Tumoral
epithelial
cells
AURKB 1,0 (0,00-3,24) 87,55 (20,39-163,71)b 118,19 (73,26-163,71) 32,90 (20,39-71,01) <0,01 1,11 3,39 5,41 22,55
TPX2 1,0 (0,31-4,23) 66,67 (23,37-123,35) 94,35 (59,99-123,35) 33,98 (23,37-47,50) <0,01 1,88 2,33 6,76 18,38
CDC20 1,0 (0,06-1,28) 25,90 (6,68-88,24) 38,68 (19,88-88,24) 10,22 (6,68-13,24) <0,01 0,77 0,48 2,42 4,99
BUB1 1,0 (0,00-1,38) 58,09 (16,34-155,96) 79,89 (39,81-155,96) 25,81 (16,34-45,41) <0,05 2,76 1,64 6,66 28,54
CCNA2 1,0 (0,05-1,45) 41,04 (9,75-79,34) 50,91 (18,64-79,34) 9,88 (9,75-38,05) <0,05 1,39 2,04 4,63 13,18
AURKA 1,0 (0,30-2,58) 40,98 (15,78-91,99) 50,68 (35,51-91,99) 20,49 (15,78-40,13) <0,05 0,93 0,77 2,96 6,53
CCNB1 1,0 (0,00-3,14) 37,66 (17,75-72,76) 55,91 (23,02-72,76) 23,26 (17,75-33,24) <0,05 1,07 1,51 4,21 13,41
BIRC5 1,0 (0,46-3,40) 70,54 (28,64-179,15) 77,44 (58,69-179,15) 47,50 (28,64-146,52) NS 1,25 2,23 6,00 14,98
CCNB2 1,0 (0,31-1,93) 41,50 (10,63-108,38) 47,34 (29,55-108,38) 19,97 (10,63-52,53) NS 0,64 1,28 3,85 10,16
BUB1B 1,0 (0,24-2,97) 36,25 (13,18-94,35) 38,72 (30,91-94,35) 25,99 (13,18-45,10) NS 0,98 1,37 4,48 17,33
PLK1 1,0 (0,30-2,08) 34,62 (9,99-50,45) 41,93 (22,68-50,45) 14,16 (9,99-37,10) NS 0,55 0,56 2,62 4,73
TACC3 1,0 (0,00-1,35) 27,86 (9,94-69,07) 37,88 (12,24-69,07) 19,29 (9,94-33,75) NS 1,82 1,52 3,15 7,50
NDC80 1,0 (0,00-1,39) 24,71 (5,70-209,38) 45,05 (5,70-209,38) 9,62 (6,92-16,37) NS 1,60 1,10 6,45 17,23
CDC2 1,0 (0,00-2,11) 23,84 (6,26-76,46) 30,34 (8,86-76,46) 23,48 (6,26-13,24) NS 0,90 0,49 4,13 11,99
NEK2 1,0 (0,16-2,87) 20,70 (5,45-62,25) 20,63 (6,53-62,25) 20,77 (5,45-40,32) NS 1,71 0,94 4,12 4,37
TTK 1,0 (0,01-7,32) 17,95 (3,23-75,41) 25,75 (6,50-75,41) 12,73 (3,23-21,51) NS 1,21 4,64 4,68 10,34
ZWINT 1,0 (0,00-3,71) 13,21 (3,97-34,14) 11,69 (3,97-34,14) 13,80 (4,32-17,51) NS 0,60 0,62 1,64 4,03
CENPE 1,0 (0,03-4,58) 8,46 (0,33-14,83) 10,34 (0,87-12,27) 3,51 (0,33-14,83) NS 1,09 0,83 1,78 10,08
CCNB3 1,0 (0,00-6,11) 3,87 (0,27-120,26) 3,35 (0,27-120,26) 4,39 (0,50-30,48) NS 0,33 2,55 0,92 1,56
UBD 1,0 (0,00-3,07) 0,01 (0,00-11,39) 0,01 (0,00-0,13) 0,01 (0,00-11,39) NS 0,06 2,56 0,26 0,49
MKI67 1,0 (0,03-5,99) 27,75 (7,38-54,07) 29,45 (13,36-54,07) 26,72 (7,38-31,78) NS 0,95 0,86 3,99 16,00
aMann and Whitney’s U Test: ERa-positive cell lines vs ERa-negative cell lines. NS, not significant.
bMedian (range) of gene mRNA levels. The mRNA levels of the tumor cell lines, fibroblasts and epithelial cells samples were normalized such that the median of
the 9 normal breast tissues mRNA levels was 1.
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AURKA lies within a region of human chromosome arm
20q13 that is amplified in breast cancer [4], as con-
firmed here (Table 5). Further in vitro studies (cultured
cells) and in vivo studies (animal models) will be
required for full confirmation of the role of these two
genes in the molecular mechanisms leading to breast
cancer aneuploidy.
Based on our two-gene expression signature, we subdi-
vided the patient population (n = 47) into three groups
with significantly different ploidy, namely a DNA diploid
group (n = 17), a DNA aneuploid group (n = 19), and an
intermediate group (n = 11) including both DNA aneu-
ploid and DNA diploid tumors (figure 3). Interestingly, the
SPF values of all the DNA diploid tumors in the inter-
mediate group were high, confirming the relationship
between aneuploidy and proliferation. A large prospective
randomized study will be necessary to confirm the exis-
tence of this intermediate group and to determine the
diagnostic and prognostic relevance of these 3 subgroups.
It is also noteworthy that the expression of the TERT
gene, encoding telomerase reverse transcriptase, was sig-
nificantly upregulated in DNA aneuploid breast tumors
compared to DNA diploid breast tumors, confirming
that aneuploidy may also be caused by telomere erosion
[12].
Based on this two-gene expression signature, some
DNA tetraploid tumor samples failed to cluster in the
DNA aneuploid breast tumor group, in keeping with the
observation that aneuploidy can be preceded by tetra-
ploidy [26].
In conclusion, this study confirms the strong relation-
ship between aneuploidy and proliferation. Among a
panel of 76 mitotic spindle checkpoint genes, we identi-
fied several genes of interest whose expression status
might serve to guide individual breast cancer patient
management. Some of the genes identified here are
already used to predict tumor recurrence and the
response to treatment, while AURKA and PLK1 are fre-
quently included in “poor prognosis” signatures
[17,18,27]. Multivariate analyses will be necessary to
assess the potential of our 2-gene signature as compa-
rated to existing gene-expression signatures such as
Mammaprint® and Oncotype DX®, and a already identi-
fied gene expression signature of genomic instability to
improve grading of breast tumors [28] or to predict the
clinical outcome of breast cancer patients [29]. AURKA
Table 5 Relationship between the mRNA expression levels and DNA amplification levels of the 20 markedly
upregulated genes
Genes Chromosome
location
Normal breast
tissues
(n = 6)
Breast tumors
(n = 39)
Unamplified tumors Amplified tumors pa
Number mRNA level Number mRNA level
CDC20 1p34.1 1,0 (0,61-1,28) 2,89 (0,39-22,65)b 38 (97,5%) 2,99 (0,54-22,65) 1 (2,5%) 0,39 NS
NEK2 1q31,2-q41 1,0 (0,44-5,23) 28,41 (2,46-137,03) 12 (30,8%) 26,55 (2,66-51,92) 27 (69,2%) 28,41 (2,46-137,03) NS
BUB1 2q14 1,0 (0,53-1,51) 5,52 (0,74-25,63) 36 (92,3%) 5,43 (0,74-25,63) 3 (7,7%) 6,39 (3,46-17,15) NS
TACC3 4p16,3 1,0 (0,54-2,08) 7,32 (1,01-29,89) 38 (97,5%) 7,09 (1,01-29,89) 1 (2,5%) 15,32 NS
CENPE 4q21-q25 1,0 (0,02-2,06) 14,59 (0,08-61,89) 38 (97,5%) 14,64 (0,08-61,89) 1 (2,5%) 5,54 NS
CCNA2 4q25-q31 1,0 (0,56-1,90) 10,39 (2,20-37,31) 36 (92,3%) 10,12 (2,2-37,31) 3 (7,7%) 22,65 (3,81-32,82) NS
CCNB1 5q12 1,0 (0,42-2,32) 4,18 (0,34-22,47) 34 (87,2%) 3,53 (0,34-18,96) 5 (12,8%) 8,88 (2,67-22,47) 0,01
UBD 6p21.3 1,0 (0,31-3,91) 4,75 (0,15-106,40) 32 (82,1%) 4,89 (0,15-106,40) 7 (17,9%) 2,93 (0,54-7,43) NS
TTK 6q13-q21 1,0 (0,71-2,08) 6,72 (0,61-44,27) 37 (94,9%) 6,72 (0,61-44,27) 2 (5,1%) 15,91 (5,85-25,96) NS
CDC2 10q21.1 1,0 (0,68-2,66) 9,52 (1,19-56,17) 34 (87,2%) 8,44 (1,19-56,17) 5 (12,8%) 17,47 (12,74-42,86) 0,03
ZWINT 10q21-q22 1,0 (0,62-1,97) 5,38 (1,08-20,70) 32 (82,1%) 4,44 (1,08-20,70) 7 (17,9%) 12,52 (4,46-18,27) 0,003
BUB1B 15q15 1,0 (0,53-1,69) 10,48 (1,35-32,33) 34 (87,2%) 9,05 (1,35-32,33) 5 (12,8%) 17,33 (10,48-27,28) 0,04
CCNB2 15q21.2 1,0 (0,64-1,95) 14,21 (2,00-68,51) 35 (89,7%) 10,15 (2,0-55,08) 4 (10,2%) 21,41 (19,34-68,51) 0,03
PLK 16p12.1 1,0 (0,60-1,87) 5,46 (0,69-35,59) 16 (41,0%) 4,49 (0,69-21,61) 23 (59,0%) 5,46 (1,24-35,59) NS
AURKB 17p13.1 1,0 (0,90-2,08) 5,82 (0,00-64,52) 39 (100%) 5,82 (0-64,52) 0 - -
BIRC5 17q25 1,0 (0,37-2,0) 14,84 (1,47-150,30) 27 (69,2%) 9,96 (1,47-49,07) 12 (30,8%) 32,31 (5,84-150,30) 0,0008
NDC80 18p11.31 1,0 (0,29-1,23) 6,28 (1,05-126,38) 34 (87,2%) 5,69 (1,05-27,22) 5 (12,8%) 27,32 (4,13-126,38) 0,03
TPX2 20q11.2 1,0 (0,59-1,48) 15,69 (1,65-117,11) 22 (56,4%) 10,26 (1,65-34,46) 17 (43,6%) 24,03 (5,45-117,11) 0,002
AURKA 20q13.2-q13.3 1,0 (0,36-1,33) 7,14 (1,46-34,22) 24 (61,5%) 5,08 (1,46-32,82) 15 (38,5%) 14,04 (3,40-34,22) 0,002
CCNB3 Xp11 1,0 (0,96-4,20) 5,65 (0,00-61,53) 33 (84,6%) 4,76 (0,00-61,53) 6 (15,4%) 11,58 (5,16-25,25) NS
aMann and Whitney’s U Test: amplified breast tumors vs unamplified breast tumors. NS, non significant.
bMedian (range) of gene mRNA levels. The mRNA levels of the tumor samples were normalized such that the median of the 6 normal breast tissues mRNA level
was 1.
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amplification induces resistance to taxol [30] and several
aurora kinase inhibitors and polo-like kinase 1 inhibitors
are in the preclinical development phase [6,31-33].
Finally, the finding that NDC80/HEC1 is involved early
in breast carcinogenesis suggests that it too may have
clinical relevance.
Materials and methods
Patients and Samples
To characterize gene expression signatures associated
with breast tumor ploidy, we analyzed samples of 47 pri-
mary breast tumors (23 DNA aneuploid and 24 DNA
diploid tumors) excised from women at our institution.
Samples containing more than 70% of tumor cells were
considered suitable for this study. Tumor cellularity was
assessed on hematoxylin and eosin-stained tissue sec-
tions. Immediately after surgery the tumor samples were
The samples were placed in liquid nitrogen until RNA
extraction.
The patients met the following criteria: primary unilat-
eral non metastatic breast carcinoma; complete clinical,
histological and biological information available; no
radiotherapy or chemotherapy before surgery; and full
follow-up at our institution.
Estrogen receptor, progesterone receptor and ERBB2
status was determined at the protein level by biochem-
ical methods (dextran-coated charcoal method, enzy-
matic immuno-assay or immunohistochemistry) and
confirmed by ERa, PR and ERBB2 real-time quantitative
RT-PCR assays. Using RH (ERa and PR) and ERBB2
status, we subdivided the total population (n = 47) into
4 subgroups, i.e. HR+ (ER+ and/or PR+)/ERBB2+ (n =
10), HR+ (ER+ and/or PR+)/ERBB2- (n = 32), HR- (ER-
and PR-)/ERBB2+ (n = 1), and HR- (ER- and PR-)/
ERBB2- (n = 4).
Standard prognostic factors are shown in Table 6. The
median follow-up was 7,8 years (range 26 months to
11.25 years).
The patients had physical examinations and routine
chest radiography every 3 months for 2 years, then
annually. Mammograms were done annually.
To validate and explore our gene expression signature
associated with tumor ploidy, we analyzed 14 additional
DNA aneuploid breast tumors, comprising 6 classical
aneuploid and 8 DNA tetraploid breast tumor.
To investigate the relationship between the mRNA
levels of candidate genes and breast cancer progression,
we also analyzed the RNA of 14 benign breast tumors,
14 ductal carcinoma in situ (DCIS) of the breast, 11
invasive ductal grade I breast tumors, and 12 invasive
ductal grade III breast tumors. Standard prognostic fac-
tors for the 11 invasive ductal grade I breast tumors and
12 invasive ductal grade III breast tumors are indicated
in Additional File 2, along with standard prognostic
factors for the 10 invasive breast tumors used for initial
screening of the dysregulated genes.
Patients’ consent and approval from the Local Ethical
Committee (Breast Group of René Huguenin Hospital)
was obtained prior to the use of these clinical materials
for research purposes in agreement to the Declaration
of Helsinki. The biological collection has been recorded
at the French Ministry of Research (N° DC-2008-355).
Table 6 Characteristics of the 24 DNA diploid and 23
DNA aneuploid breast tumors
Human breast tumors
(n = 47)
DNA diploid
breast tumors
(n = 24)
DNA aneuploid
breast tumors
(n = 23)
Pa
Age
≤ 05 2 (8.3%) 1 (4.3%) NS
> 50 22 (91.7%) 22 (95.7%)
SBR histological
grade b
I 9 (37.5%) 2 (8.7%) 0.0061
II 12 (50%) 9 (39.1%)
III 3 (12.5%) 12 (52.2%)
Lymph node
status
Negative 14 (58.3%) 15 (65.2%) NS
Positive 10 (41.7%) 8 (34.8%)
Macroscopic
tumor size
≤ 20 mm 12 (50%) 11 (48%) NS
> 20 mm 12 (50%) 12 (52%)
PR status
Negative 3 (12.5%) 8 (34.8%) NS
Positive 21 (87.5%) 15 (65.2%)
ER status
Negative 0 (0%) 7 (30.4%) 0.012
Positive 24 (100%) 16 (69.6%)
ERBB2 status
Negative 19 (79.2%) 17 (73.9%) NS
Positive 5 (20.8%) 6 (26.1%)
Molecular
subtypes
RH- ERBB2- 0 (0%) 4 (17.4%) NS
RH- ERBB2
+
0 (0%) 1 (4.4%)
RH+
ERBB2-
19 (79.2%) 13 (56.5%)
RH+ ERBB2
+
5 (20.8%) 5 (21.7%)
Histologic types
Ductal 21 (87.5%) 23 (100%) NS
Lobular 2 (8.3%) 0
Tubular 1 (4.2%) 0
aChi2 test.
b: Scarff Bloom Richardson classification.
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Table 7 mRNA expression of the 49 dysregulated genes in aneuploid tumors relative to diploid tumors
Genes Diploid tumors
(n = 24)
Aneuploid tumor
(n = 23)
pa ROC-AUCb
PLK1 1,67 (0,69-7,46)c 8,65 (2,26-35,59) 0,0000005 0,929
AURKA 4,41 (1,46-15,80) 12,92 (3,88-34,22) 0,0000006 0,924
CCNB1 2,23 (0,34-19,16) 5,56 (2,67-18,97) 0,000002 0,901
BUB1 2,96 (0,74-10,74) 6,75 (1,88-25,63) 0,00008 0,837
CDC20 1,76 (0,39-7,95) 4,70 (1,39-22,65) 0,0001 0,824
TACC3 3,81 (1,01-12,27) 8,47 (2,62-29,89) 0,0002 0,814
CDC2 4,77 (1,19-23,21) 14,39 (3,51-56,17) 0,0005 0,797
ZWINT 3,74 (1,08-14,24) 5,97 (2,61-20,70) 0,0005 0,795
BUB3 1,73 (0,74-3,63) 2,89 (1,08-10,17) 0,0007 0,789
NDC80 4,30 (1,05-23,45) 10,00 (2,96-126,38) 0,0009 0,784
TPX2 9,63 (1,65-35,79) 22,11 (5,45-117,11) 0,0009 0,783
RAD21 1,61 (0,65-5,69) 3,03 (0,78-10,73) 0,001 0,770
MAD2L2 1,20 (0,39-3,66) 1,91 (0,61-7,41) 0,002 0,767
CDC23 1,27 (0,92-2,89) 1,96 (0,95-3,96) 0,002 0,765
PPP1R2 1,94 (0,83-3,46) 2,64 (1,03-4,91) 0,004 0,733
CENPE 7,58 (0,08-39,17) 17,11 (2,88-61,89) 0,007 0,729
PTTG1 2,60 (0,01-12,91) 4,03 (2,34-9,95) 0,007 0,729
BIRC5 9,76 (1,47-43,46) 23,21 (2,32-150,30) 0,007 0,728
AURKB 3,83 (0,61-20,14) 6,62 (1,02-64,52) 0,008 0,726
CCNB2 7,74 (2,00-68,51) 17,86 (3,53-55,08) 0,01 0,714
KNTC1 1,02 (0,44-3,63) 1,75 (0,50-3,70) 0,01 0,710
TTK 4,20 (0,61-16,04) 8,05 (1,72-44,27) 0,02 0,701
CCNA2 7,62 (2,45-32,82) 13,61 (2,20-35,30) 0,02 0,692
ESPL1 2,09 (0,44-9,64) 4,59 (0,68-10,11) 0,04 0,674
CDKN1A 1,50 (0,49-3,87) 2,08 (0,76-10,29) NS 0,657
MAD2L1 1,92 (0,80-8,58) 2,34 (1,08-5,18) NS 0,647
SMC1L2 0,19 (0,00-2,15) 0,70 (0,04-10,43) NS 0,642
NEK2 18,34 (2,46-109,01) 29,31 (4,97-137,03) NS 0,638
FBXW7 0,47 (0,16-1,30) 0,61 (0,30-1,18) NS 0,631
BUB1B 6,32 (1,35-63,78) 11,35 (3,25-27,28) NS 0,626
UBD 3,47 (0,15-41,74) 4,94 (0,44-106,40) NS 0,605
CCNB3 5,90 (0,75-27,35) 6,77 (1,29-61,53) NS 0,601
CDC27 1,69 (0,74-2,46) 1,90 (0,65-5,77) NS 0,599
ANAPC4 0,86 (0,31-1,84) 0,90 (0,38-1,90) NS 0,592
MRE11A 0,72 (0,25-1,46) 0,89 (0,21-2,31) NS 0,592
ZWILCH 1,79 (0,76-4,98) 2,26 (0,98-3,50) NS 0,589
BRCA2 1,37 (0,31-7,84) 2,06 (0,69-4,87) NS 0,581
UBE2N 2,08 (1,53-3,42) 2,34 (1,58-3,42) NS 0,574
RAN 1,88 (1,05-3,33) 2,09 (1,28-15,85) NS 0,550
STAG1 0,56 (0,23-1,03) 0,58 (0,31-0,94) NS 0,549
RAE1 2,03 (1,37-4,32) 2,14 (1,15-2,88) NS 0,519
AURKC 0,77 (0,37-3,08) 0,75 (0,35-10,67) NS 0,496
AURKAIP1 2,00 (0,77-3,55) 1,83 (1,05-3,93) NS 0,466
PPP1CA 2,57 (1,23-9,80) 2,15 (1,26-11,11) NS 0,440
TACC1 1,14 (0,26-2,93) 0,99 (0,23-2,81) NS 0,430
RASSF1A 0,55 (0,10-2,13) 0,46 (0,16-1,35) NS 0,413
ANAPC7 2,32 (1,33-4,41) 2,22 (1,39-3,46) NS 0,399
PRCC 3,67 (1,94-6,62) 2,96 (1,62-6,35) NS 0,388
UBE1C 1,70 (0,67-3,71) 1,41 (0,52-2,65) NS 0,384
ANAPC2 1,05 (0,46-2,63) 0,95 (0,57-1,62) NS 0,365
FZR1 0,75 (0,29-1,49) 0,56 (0,24-1,41) 0,001 0,225
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Table 7 mRNA expression of the 49 dysregulated genes in aneuploid tumors relative to diploid tumors (Continued)
HTERT 1,00 (0,51-4,11) 1,69 (0,33-28,84) 0,04 0,678
MKI67 1,00 (0,20-4,70) 2,20 (0,72-7,41) 0,0009 0,782
ESR1 1,00 (0,29-2,78) 0,89 (0,00-3,77) NS 0,426
aKruskal Wallis’ H Test.
bROC (Receiver Operating Characteristics) - AUC (Area Under the Curve) analysis.
cMedian (range) gene mRNA levels. The mRNA levels of the tumor samples were normalized such that the median of the 9 normal breast tissues mRNA levels was 1.
63.6%
(7D/4A)
94.1%
P = 0.0000015
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Figure 3 Dendrogram of 24 DNA diploid (xxxx-D) and 23 DNA aneuploid breast tumors (xxxx-A). We constructed the dendogram by
hierarchical clustering, according to PLK1 and AURKA expression. The SPF value, categorized as low, intermediate or high, is indicated for each
tumor. The percentages of diploid breast tumors in each subgroup are indicated on the right.
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Figure 4 Dendrogram of 24 DNA diploid, 23 DNA aneuploid and 6 additional DNA aneuploid breast tumors. We constructed by
hierarchical clustering, a dendrogram of 24 DNA diploid (xxxx-D), 23 DNA aneuploid (xxxx-A) and 6 additional DNA aneuploid breast tumors
(xxxx-A-new; solid line rectangle), according to PLK1 and AURKA expression. The SPF value for each tumor, categorized as low, intermediate or
high, is indicated on the right.
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Figure 5 Dendogram of 24 DNA diploid, 23 DNA aneuploid and 8 DNA tetraploid breast tumors. We constructed by hierarchical
clustering, a dendrogram of 24 DNA diploid (xxxx-D), 23 DNA aneuploid (xxxx-A) and 8 DNA tetraploid breast tumors (xxxx-T; solid line
rectangle), according to PLK1 and AURKA expression. SPF value, categorized as low, intermediate or high, for each tumor is indicated on the
right.
Bièche et al. Molecular Cancer 2011, 10:23
http://www.molecular-cancer.com/content/10/1/23
Page 15 of 18
Finally, we analyzed five ERa-positive cell lines (MCF7,
HCC1500, T-47D, ZR-75-1 and MDA-MB361) and seven
ERa-negative cell lines (SK-BR-3, HBL-100, BT-20, MDA-
MB157, MDA-MB231, MDA-MB435s and MDA-MB468),
obtained from the American Tissue Type Culture Collection.
Nine specimens of adjacent normal breast tissue from
breast cancer patients or normal breast tissue from
women undergoing cosmetic breast surgery were used
as sources of normal RNA.
Primary cell culture and differential isolation of epithelial
cells and fibroblasts from normal breast tissues and
breast tumor cells
To determine which cells (epithelial cells and/or fibro-
blasts) overexpressed mitotic-spindle-checkpoint genes,
we measured the RNA levels of the selected genes in
primary cultures of epithelial cells and fibroblasts from
normal breast tissues and breast tumor cells.
Breast tumors and normal tissues were minced with a
scalpel and incubated overnight with Liberase Blend-
zyme 2 (Roche Applied Science, Meylan, France) for
enzymatic dispersion. Organoids and aggregated cells
(epithelial fraction) and isolated cells (fibroblast fraction)
were separated by filtration and centrifugation. The
fibroblast fraction was cultured in Ham’s F10 medium
containing L-glutamine (3 mM), insulin (5 mg/mL), T3
(1 nM), hydrocortisone (1 mg/mL), kanamycin (0.1 mg/
mL), and 10% fetal calf serum. The epithelial fraction
was cultured in the same conditions, plus epidermal
growth factor (5 ng/mL), transferrin (5 mg/mL) and 5%
human serum (instead of fetal calf serum). Cells were
incubated in humidified air with 5% CO2 at 37°C, and
the medium was changed three times a week. Cells were
cultured for two weeks before RNA extraction. Epithelial
cells and fibroblasts were identified by their morphologi-
cal features and by detecting epithelial (keratin 19) and
fibroblast marker expression with real-time RT-PCR.
Flow cytometric DNA analysis and S-phase fraction (SPF)
classification
Cell preparation and DNA staining were performed as
previously described [34]. Flow cytometry (FCM) was
performed on a FACScalibur device (Becton Dickinson,
CA, USA). Cell cycle analysis was performed with the
Modfit LT 2.0 program (Verity Software House, Top-
sham, ME). The DNA-diploid peak was located on DNA
histograms by using an external standardization proce-
dure with normal human lymphocytes positioned in the
fifth part of the red fluorescence scale. DNA ploidy and
the S-phase fraction (SPF) were obtained after gating on
a dot plot (FL2-width versus FL2-area), selecting a repre-
sentative amount of debris and excluding doublets.
The DNA ploidy pattern was expressed as the DNA
index (DI) that is the ratio between the mean
fluorescence channel number of the tumor G0/G1 peak
and the diploid G0/G1 reference peak. Rules established
during a previous inter-laboratory control procedure
[35] were applied when using the cell-cycle software
models. The tumors were classified as follows based on
the DNA index. A tumor showing a single peak with a
DNA index comprised between 0.95 and 1.1 was classi-
fied as DNA diploid; if an additional peak was present,
the tumor was placed in one of the following DNA
aneuploid subcategories, if they contain at least 10% of
total cell counts and a corresponding G2M peak: DNA
aneuploid with a DI comprised between 1.10 and 1.90
and > 2.05; DNA tetraploid with a DI comprised
between 1.90 and 2.05. There were no hypodiploid (DI
< 0.95) or multiploid (several aneuploid peaks) tumors
in this series. The ploidy-adjusted SPF was categorized
as low, intermediate or high, based on the 33rd and
66th percentiles. The debris and aggregate subtraction
options were used when appropriate.
Real-time RT-PCR
(1) RNA extraction
Total RNA was extracted from breast specimens by
using the acid-phenol guanidium method. The quantity
of the RNA samples was accurately measured by using a
NanoDrop spectrophotometer, and their quality was
determined by electrophoresis through agarose gel stain-
ing with ethidium bromide, and visualization of the 18S
and 28S RNA bands under ultraviolet light.”
(2) Theoretical basis
Real-time PCR reactions are characterized by the point
during cycling when amplification of the PCR product is
first detected, rather than the amount of PCR product
accumulated after a fixed number of cycles. The para-
meter Ct (threshold cycle) is defined as the fractional
cycle number at which the fluorescence generated by
cleavage of a TaqMan probe (or by SYBR green dye-
amplicon complex formation) passes a fixed threshold
above baseline. The increase in the fluorescence signal
associated with exponential growth of PCR products is
detected by the laser detector of the ABI Prism 7700
Sequence Detection System (Perkin-Elmer Applied Bio-
systems, Foster City, CA), using PE Biosystems analysis
software, according to the manufacturer’s manuals.
The precise amount of total RNA added to each reaction
mix (based on optical density) and its quality (i.e. lack of
extensive degradation) are both difficult to assess. We
therefore also quantified transcripts of two endogenous
RNA control genes involved in two cellular metabolic
pathways, namely TBP (Genbank accession NM_003194),
which encodes the TATA box-binding protein, and
RPLP0 (NM_001002), which encodes human acidic ribo-
somal phosphoprotein P0. Each sample was normalized
on the basis of its TBP (or RPLPO) content.
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Results, expressed as N-fold differences in target gene
expression relative to the TBP (or RPLPO) gene,
and termed “Ntarget“, were determined as Ntarget =
2∆Ctsample, where the ∆Ct value of the sample is deter-
mined by subtracting the average Ct value of the target
gene from the average Ct value of the TBP (or RPLP0)
gene [36,37].
The Ntarget values of the samples were subsequently
normalized such that the median of the nine normal
breast tissue Ntarget values was 1.
(3) Primers and controls
Primers for TBP, RPLP0 and the 76 target genes were
chosen with the assistance of the Oligo 5.0 computer
program (National Biosciences, Plymouth, MN).
To avoid amplification of contaminating genomic
DNA, one of the two primers was placed at the junction
between two exons. In general, amplicons were between
70 and 120 nucleotides long. Gel electrophoresis was
used to verify the specificity of PCR amplicons.
The 76 target genes tested in this study are listed in
Table 1. They were selected from the literature for their
potential involvement in molecular mechanisms asso-
ciated with the mitotic spindle checkpoint.
cDNA synthesis and PCR conditions were as described
elsewhere [37]. Experiments were performed with dupli-
cates for each data point. All patient samples with a CV
of Ct values higher than 10% were retested.
High-resolution array CGH (comparative genomic
hybridization)
Tumor samples were analyzed with the Agilent Human
Genome CGH Microarray 44K. DNA samples for array
CGH were labeled as previously described [38]. Briefly, 1
μg each of breast tumor DNA and commercial pooled
human normal genomic DNAs (Promega, Madison, WI)
was digested with 5 μg of AluI (50 units) and 5 ml of
RsaI (50 units) (Promega, Madison, WI) and labeled by
random priming with CY3- and CY5-dUTP, respectively
(Agilent Technologies, Massy, France). The labeled solu-
tions were then filtered on a Microcon YLM-30 column
(Millipore, Billerica, MA), denatured and hybridized
with unlabeled Cot-1 DNA (Invitrogen, Carlsbad, CA) to
the CGH arrays. After hybridization in an oven rotating
at 15 rpm (Model1012, Sheldon Manufacturing, Corne-
lius, OR), the slides were washed and scanned with the
Agilent G2565AA Microarray Scanner.
Statistical Analysis
As the mRNA levels did not fit a Gaussian distribution, (a)
the mRNA levels in each subgroup of samples were
expressed as the median and range rather than the mean
and coefficient of variation, and (b) relationships between
the molecular markers and clinical and histological para-
meters were analyzed with the chi-square test (link
between two qualitative parameters) or the non parametric
Mann-Whitney U test (link between one qualitative para-
meter and one quantitative parameter) [39]. Differences
between two populations were considered significant at
confidence levels greater than 95% (p < 0.05).
To visualize the capacity of a given molecular marker
to discriminate between two populations (in the absence
of an arbitrary cutoff value), we summarized the data in a
ROC (receiver operating characteristics) curve [40]. ROC
curves plot sensitivity (true positives) on the Y axis
against 1-specificity (false positives) on the X axis, con-
sidering each value as a possible cutoff. The AUC (area
under curve) was calculated as a single measure of the
discriminatory capacity of each molecular marker. When
a molecular marker has no discriminatory value, the
ROC curve lies close to the diagonal and the AUC is
close to 0.5. In contrast, when a molecular marker has
strong discriminatory value, the ROC curve moves to the
upper left-hand corner and the AUC is close to 1.0.
A gene expression signature associated with tumor
ploidy was sought with the BRB Array Tools program,
using the Prediction Analysis for Microarrays (PAM)
and Class Prediction results modules.
Hierarchical clustering was performed with Gen-
ANOVA software [41].
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